NUVO going for holy grail - Cancer!NUVO going for holy grail - Cancer!
Anyone that has a warm connection to NUVO knows the long history of Transdermal tech...even average researchers find this boaring. These "test tube sniffers" are really after Cancer! They only need a "easy" revenue stream so they can go after the BIG-ONE!
""
Immune Regulation PlatformNuvo's second technology platform is based on a chlorite solution code-named WF10.
The immune system provides an essential defence to micro organisms,tumors and substances it sees as foreign and potentially harmful.Nuvo's immune regulation technology platform focuses on supporting theimmune system by targeting the macrophage, a type of white blood cellthat coordinates much of the immune system, to regulate normal immune function.
WF10 is based on a chlorite solution of TCDO that appears toact on the macrophage, a white blood cell species with a central role in controllingthe body's immune response. Normally functioning macrophages alternate between one oftwo basic states: phagocytic and inflammatory. Phagocytic macrophages digest invadingorganisms, such as viruses, and initiate a biological inflammatory defence pathway.Inflammatory macrophages, in turn, induce a variety of reactions, including fever, sweating,swollen glands, malaise and appetite loss, the common, uncomfortable signs of illness.Such responses, while entirely normal, must be turned on and off in a controlled manner.If left unchecked pathogens can overdrive the system toward the inflammatory state creatingan imbalance that may lead to such medical disorders as autoimmune disease, organ damage andtumour proliferation.The Corporation's WF10 technology's proposed mode of activity is based on a theoryabout how the macrophage regulates the immune system. Research suggests the drug maycorrect improperly functioning immune systems. The drug has potential applications inadjuvant cancer therapy, immunology, and the management of chronic viral infections.""
Nuvo Research Inc.